Literature DB >> 20854468

Immunohistochemical characteristics of diffuse sclerosing variant of papillary carcinoma: comparison with conventional papillary carcinoma.

Ja Seung Koo1, Eunah Shin, Soon Won Hong.   

Abstract

Diffuse sclerosing variant of papillary carcinoma (DSVPC) is a rare variant of papillary thyroid carcinoma (PTC). It shows different clinicopathologic features to the conventional PTC, but the immunohistochemical characteristics of DSVPC are yet to be more clearly defined. The purpose of this study was to investigate the immunohistochemical features of DSVPC, which are different from those of PTC. Tissue microarray was constructed from the paraffin-embedded tissue of 49 DSVPC and 50 conventional PTC samples. Immunohistochemical stains for p63, p53, galectin-3, cytokeratin 19, β-catenin, Bcl-2, EMA, E-cadherin, CD15, and CD56 were performed on each tissue microarray. Immunohistochemical stain for p63 was negative in all conventional PTCs, but 14 (28.6%) cases of DSVPC showed p63 expression (p = 0.000). p53 was expressed in 38 (76.0%) cases of conventional PTC and 21 (42.9%) cases of DSVPC (p = 0.001). Galectin-3 was expressed in all 50 cases of conventional PTC, but eight (16.3%) cases of DSVPC did not express galectin-3 (p = 0.003). EMA was expressed more in DSVPC (40.8%) than in conventional PTC (20.0%, p = 0.024). In univariate analyses, Bcl-2 positivity (p = 0.016) and EMA negativity (p = 0.036) in DSVPC were associated with shorter time interval to tumor recurrence, but there was no significance for the two in multivariate analyses. DSVPC, a rare variant of PTC, has different immunohistochemical features from the conventional PTC, showing higher expression rate of p63 and lower expression rate of p53. It also shows galectin-3 negativity and EMA positivity.
© 2010 The Authors. Journal Compilation © 2010 APMIS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854468     DOI: 10.1111/j.1600-0463.2010.02653.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

1.  Clinicopathologic features and outcomes in patients with diffuse sclerosing variant of papillary thyroid carcinoma.

Authors:  Junko Akaishi; Kiminori Sugino; Kaori Kameyama; Chie Masaki; Kenichi Matsuzu; Akifumi Suzuki; Takashi Uruno; Keiko Ohkuwa; Hiroshi Shibuya; Wataru Kitagawa; Mitsuji Nagahama; Kazuo Shimizu; Koichi Ito
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

2.  Surgical Management of Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma. Experience in 25 Patients.

Authors:  Claudio Spinelli; Silvia Strambi; Sohail Bakkar; Andrea Nosiglia; GianMarco Elia; Alessia Bertocchini; Chiara Calani; Matteo Leoni; Riccardo Morganti; Gabriele Materazzi
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

3.  Stage-Specific Embryonic Antigen-1 (SSEA-1) Expression in Thyroid Tissues.

Authors:  Jin Xu; Heather Hardin; Ranran Zhang; Kaitlin Sundling; Darya Buehler; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

4.  Estrogen receptor- and progesterone receptor-positive diffuse sclerosing variant of papillary thyroid carcinoma: a case report.

Authors:  Yuichi Kinoshita; Kosho Takasu; Takashi Yuri; Kastuhiko Yoshizawa; Yuko Emoto; Airo Tsubura; Nobuaki Shikata
Journal:  Case Rep Oncol       Date:  2013-04-06

5.  Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma.

Authors:  Yanhong Huang; Wenwu Dong; Jing Li; Hao Zhang; Zhongyan Shan; Weiping Teng
Journal:  BMC Cancer       Date:  2014-05-29       Impact factor: 4.430

Review 6.  Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.

Authors:  Andrés Coca-Pelaz; Jatin P Shah; Juan C Hernandez-Prera; Ronald A Ghossein; Juan P Rodrigo; Dana M Hartl; Kerry D Olsen; Ashok R Shaha; Mark Zafereo; Carlos Suarez; Iain J Nixon; Gregory W Randolph; Antti A Mäkitie; Luiz P Kowalski; Vincent Vander Poorten; Alvaro Sanabria; Orlando Guntinas-Lichius; Ricard Simo; Peter Zbären; Peter Angelos; Avi Khafif; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2020-06-01       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.